PT  - JOURNAL ARTICLE
AU  - Funmilayo I. Tade
AU  - Rebecca A. Sajdak
AU  - Mehdat Gabriel
AU  - Robert H. Wagner
AU  - Bital Savir-Baruch
TI  - Best Practices for <sup>18</sup>F-Fluciclovine PET/CT Imaging of Recurrent Prostate Cancer: A Guide for Technologists
AID  - 10.2967/jnmt.119.227116
DP  - 2019 Dec 01
TA  - Journal of Nuclear Medicine Technology
PG  - 282--287
VI  - 47
IP  - 4
4099  - http://tech.snmjournals.org/content/47/4/282.short
4100  - http://tech.snmjournals.org/content/47/4/282.full
SO  - J. Nucl. Med. Technol.2019 Dec 01; 47
AB  - 18F-fluciclovine is a Food and Drug Administration–approved PET tracer indicated for patients suspected to have recurrent prostate cancer based on a prostate-specific antigen rise after prior therapy. 18F-fluciclovine PET/CT is performed significantly differently from 18F-FDG PET/CT and requires special attention to patient preparation, injection technique, and imaging time. This article aims to provide nuclear medicine technologists with the best-practice guidelines for the 18F-fluciclovine PET/CT protocol.